Clinical Trials Sponsored by NovoCure Ltd.

Total 16930 results

NovoCure GmbH

Active, not recruiting

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NSCLC | Nonsmall Cell Lung Cancer

United States, Poland, Hong Kong, China, Spain, Serbia, Croatia, France, Canada, Netherlands, Austria, Belgium, Bulgaria, Czechia, Germany, Hungary, Italy, Switzerland
NovoCure GmbH

Active, not recruiting

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

United States, China, Israel, Spain, Austria, Canada, Hong Kong, Germany, France, Bulgaria, Croatia, Hungary, Italy, Poland, Serbia
NovoCure GmbH

Unknown

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

Hepatocellular Carcinoma

Italy, Czechia, France, Germany, Poland, Spain
NovoCure Ltd.

Unknown

TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM

Glioblastoma Multiforme

Israel
NovoCure Ltd.

Completed

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Malignant Pleural Mesothelioma

Netherlands, Italy, Germany, Belgium, France, Poland, Spain
NovoCure Ltd.

Unknown

Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)

1-5 Brain Metastases From Non-Small Cell Lung Cancer

Poland, Czech Republic, Italy, France, Spain
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
NovoCure GmbH

Recruiting

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study (TIGER Meso)

Pleural Mesothelioma

Germany, Italy
NovoCure GmbH

Completed

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge

COVID-19

Israel
NovoCure GmbH

Not yet recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)

Metastatic Non-small Cell Lung Cancer
NovoCure GmbH

Active, not recruiting

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)

Glioblastoma Multiforme

United States, United Kingdom, Israel, Germany, Japan, Canada, France, Switzerland, Belgium, Czechia, Austria
NovoCure Ltd.

Recruiting

Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM

Glioblastoma Multiforme

Czechia
NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Ovarian Cancer

United States, Israel, Belgium, Netherlands, Hungary, Germany, Poland, Canada, Austria, Czechia, Italy, Spain, Switzerland
NovoCure Ltd.

Active, not recruiting

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Pancreas Adenocarcinoma

United States, China, Belgium, Czechia, Korea, Republic of, Spain, Hong Kong, France, Australia, Italy, Hungary, Germany, Croatia, Canada, Mexico, Israel, Austria, Switzerland, Brazil, Poland
NovoCure Ltd.

Unknown

TTFields In GErmany in Routine Clinical Care (TIGER)

Glioblastoma

Germany
NovoCure Ltd.

Unknown

Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)

Pancreatic Adenocarcinoma

Spain, Switzerland
NovoCure Ltd.

Completed

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States, Spain, France, Canada, Korea, Republic of, Austria, Israel, Czech Republic, Germany, Italy, Sweden, Switzerland
NovoCure Ltd.

Terminated

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

Recurrent Glioblastoma Multiforme

United States
NovoCure Ltd.

Completed

NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Switzerland
NovoCure Ltd.

Recruiting

TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study

Glioblastoma

Germany
NovoCure Ltd.

Unknown

Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)

Ovarian Carcinoma

Switzerland, Belgium, Germany, Spain
NovoCure Ltd.

Completed

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

Recurrent Glioblastoma Multiforme

United States, Israel, Switzerland, Austria, Czech Republic, France, Germany
NovoCure GmbH
Zai Lab (Shanghai) Co., Ltd.

Unknown

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer

Hong Kong
Duke University
NovoCure Ltd.

Completed

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields (ACTION)

Malignant Glioma

United States
Mayo Clinic
NovoCure Ltd.

Recruiting

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Pancreatic Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Metastatic Adenocarcinoma

United States
Stanford University
NovoCure Ltd.

Recruiting

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma | Newly Diagnosed Glioblastoma

United States
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
Brown University
NovoCure Ltd.

Not yet recruiting

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Metastatic Melanoma | Melanoma Brain Metastasis

United States
University of Florida
NovoCure Ltd.

Terminated

FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma (FORWARD)

Astrocytoma, Grade III | Astrocytoma, Grade II

United States
RTOG Foundation, Inc.
NovoCure Ltd.

Terminated

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Glioma | Glioblastoma | Gliosarcoma

United States
Hackensack Meridian Health
NovoCure Ltd.

Active, not recruiting

HUMC 1612: Optune NovoTTF-200A System

High Grade Glioma | Ependymoma

United States
Institut Claudius Regaud
NovoCure Ltd.

Not yet recruiting

Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma (EXOFIELDS)

Glioblastoma

France
HonorHealth Research Institute
NovoCure Ltd.

Recruiting

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Uveal Melanoma

United States
Wayne State University
NovoCure Ltd.

Completed

Tryptophan Metabolism in Human Brain Tumors

Glioblastoma

United States
University of Florida
NovoCure Ltd.

Active, not recruiting

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) (2-THE-TOP)

Glioblastoma | Glioblastoma, WHO Grade IV

United States
Hackensack Meridian Health
NovoCure Ltd.

Completed

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma, Adult

United States
University of Florida
NovoCure Ltd.

Terminated

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Glioblastoma | Glioblastoma Multiforme | Malignant Glioma | GBM

United States
Saint Luke's Health System
NovoCure Ltd.

Withdrawn

Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma

Central Nervous System Neoplasms, Primary
University of Maryland, Baltimore
NovoCure Ltd.

Terminated

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

Brain Tumor | RECURRENT GLIOBLASTOMA

United States
University of Maryland, Baltimore
NovoCure Ltd.

Unknown

Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues

Esophageal Cancer | Lung Cancer | Mesothelioma; Lung
Vanderbilt-Ingram Cancer Center
NovoCure Ltd.

Terminated

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Carcinoma

United States
Memorial Sloan Kettering Cancer Center
NovoCure Ltd.

Recruiting

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Adenocarcinoma of Lung

United States
Albert Einstein College of Medicine
NovoCure Ltd.

Active, not recruiting

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Glioblastoma

United States
Wake Forest University Health Sciences
NovoCure Ltd.

Terminated

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Cancer of Brain and Nervous System

United States
Washington University School of Medicine
NovoCure Ltd.

Terminated

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Melanoma With Brain Metastasis

United States
University of Pennsylvania
Tesaro, Inc.; NovoCure Ltd.

Active, not recruiting

Niraparib/TTFields in GBM

Glioblastoma | GBM | Recurrent Glioblastoma

United States
Aarhus University Hospital
NovoCure Ltd.

Completed

Enhancing Optune Therapy With Targeted Craniectomy

Glioblastoma

Denmark
Michael Chuong
NovoCure Ltd.

Recruiting

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Pancreas Cancer | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced

United States
Emory University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Metastatic Melanoma | Melanoma of Unknown Primary | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma | Metastatic Ocular Melanoma

United States
Northwestern University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Atypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial Meningioma

United States

Clinical Trials Sponsored by NovoCure Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations